NCT03611868 2025-08-07A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid TumorsAscentage Pharma Group Inc.Phase 1/2 Active not recruiting230 enrolled